TORONTO – Some of the most active companies traded Monday on the Toronto Stock Exchange and the TSX Venture Exchange:
Toronto Stock Exchange (15,249.99, down 16.58 points):
RB Energy Inc. (TSX:RBI). Miner. Down 14.5 cents, or 28.43 per cent, to 36.5 cents on 9.7 million shares.
Romarco Minerals Inc. (TSX:R). Miner. Up seven cents, or 8.43 per cent, to 90 cents on 5.2 million shares.
Bioniche Life Sciences Inc. (TSX:BNC). Biotechnology. Up 5.5 cents, or 17.46 per cent, to 37 cents on 4.9 million shares.
B2Gold Corp. (TSX:BTO). Miner. Down thre cents, or 1.02 per cent, to $2.91 on 4.7 million shares.
Bombardier Inc. (TSX:BBD.B): Plane, train maker. Unchanged at $3.78 on 3.9 million shares.
Toronto Venture Exchange (1,006.48, down 5.75 points):
Petroamerica Oil Corp. (TSXV:PTA). Oil and gas. Down 0.5 cents, or 1.54 per cent, to 32 cents on 41.7 million shares.
Mena Hydrocarbons Inc. (TSXV:MNH). Oil and gas. Up one cent, or 66.67 per cent, to 2.5 cents on 10.4 million shares.
Companies reporting major news:
Canadian National Railways (TSX:CNR). Transportation. Down 13 cents, or 0.18 per cent, at $72.95 on 837,761 shares. The company reported after the close that adjusted earnings per share came in at $1.03, three cents better than estimates. Its operating ratio, a key measure of performance where lower is better, moved down to 59.6 against expectations of a reading of 60.
SNC-Lavalin (TSX:SNC). Engineering. Up 18 cents, or 0.32 per cent, to $56.46 on 199,322 shares. The company has signed a contract with Stornoway Diamonds Inc. to provide project, engineering and construction management services for a diamond mine located in Quebec’s James Bay region. The value of the contract was not announced, however the company said the work included will cover roughly $425 million of the planned capital spending at the project.
Valeant Pharmaceuticals International, Inc. (VRX). Drug manufacturer. Up $3.85, or 2.94 per cent, to $134.67 on 417,302 shares. The company has complained to securities regulators in Quebec and the U.S. about what is says are misleading statements made by Allergan in its fight against the company’s hostile takeover offer. The company said Monday it has contacted the Autorite des marches financiers in Quebec and the U.S. Securities and Exchange Commission.